AD Pipeline Watch: LNK01004 Performs Well in Phase 2 Trial
LNK01004, a skin-restricted, soft pan-Janus kinase (JAK) inhibitor for the treatment of atopic dermatitis (AD), showed efficacy and safety in a Phase 2 study, according to top-line results.
Category: Atopic Dermatitis